GUANFACINE
All strengths: Limited Use — Reason for Use code 540 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 540 required
Patient paysPatient pays: program not supplied; amount cannot be determined.
Apo-Guanfacine XR · DIN 02523728 · 1mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Guanfacine XR · DIN 02523728
Manufacturer: Apotex Inc.; listing date 2022-03-31
Health Canada: Marketed since 2022-01-31 · brand APO-GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG · company Apotex inc · schedule Prescription
Apo-Guanfacine XR: Formulary list price $0.7688/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7688 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101278 · Verify on the e-Formulary ↗ (DIN 02523728)
Source record
DIN 02523728: Apo-Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816001; group id 360; item number 0840; lccId 00326; manufacturer id APX
Source form: ER Tab; strength: 1mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.7688; ministry $0.7688
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523728
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101278
Interchangeable products
Intuniv XR · DIN 02409100 · $0.7688
Jamp Guanfacine XR · DIN 02523558 · $0.7688
Sandoz Guanfacine XR · DIN 02563185 · $0.7688
Shortage status: shortage reported ended 2026-07-10 (report last updated 2026-07-10); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523728
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Intuniv XR · DIN 02409100 · 1mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Savings card: innoviCares lists Intuniv XR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Intuniv XR · DIN 02409100
Manufacturer: Takeda Canada Inc.; listing date 2020-01-31
Health Canada: Marketed since 2021-08-24 · brand INTUNIV XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG · company Takeda canada inc · schedule Prescription
Ministry pays: $0.7688 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89383 · Verify on the e-Formulary ↗ (DIN 02409100)
Source record
DIN 02409100: Intuniv XR
Raw flags: sec12=Y, sec3=Y
Item: 240816001; group id 360; item number 0840; lccId 00326; manufacturer id TAK
Source form: ER Tab; strength: 1mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.0750; ministry $0.7688
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02409100
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89383
Interchangeable products
Apo-Guanfacine XR · DIN 02523728 · $0.7688
Jamp Guanfacine XR · DIN 02523558 · $0.7688
Sandoz Guanfacine XR · DIN 02563185 · $0.7688
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02409100
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Guanfacine XR · DIN 02523558 · 1mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Guanfacine XR · DIN 02523558
Manufacturer: Jamp Pharma Corporation; listing date 2022-03-31
Health Canada: Marketed since 2022-01-27 · brand JAMP GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG · company Jamp pharma corporation · schedule Prescription
Jamp Guanfacine XR: Formulary list price $0.7688/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7688 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101263 · Verify on the e-Formulary ↗ (DIN 02523558)
Source record
DIN 02523558: Jamp Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816001; group id 360; item number 0840; lccId 00326; manufacturer id JPC
Source form: ER Tab; strength: 1mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.7688; ministry $0.7688
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523558
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101263
Interchangeable products
Apo-Guanfacine XR · DIN 02523728 · $0.7688
Intuniv XR · DIN 02409100 · $0.7688
Sandoz Guanfacine XR · DIN 02563185 · $0.7688
Shortage status: resolved shortage (ended 2025-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523558
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Guanfacine XR · DIN 02563185 · 1mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Guanfacine XR · DIN 02563185
Manufacturer: Sandoz Canada Inc.; listing date 2026-05-29
Health Canada: Marketed since 2026-04-30 · brand SANDOZ GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 1 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Guanfacine XR: Formulary list price $0.7688/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7688 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106599 · Verify on the e-Formulary ↗ (DIN 02563185)
Source record
DIN 02563185: Sandoz Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816001; group id 360; item number 0840; lccId 00326; manufacturer id SDZ
Source form: ER Tab; strength: 1mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.7688; ministry $0.7688
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02563185
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106599
Interchangeable products
Apo-Guanfacine XR · DIN 02523728 · $0.7688
Intuniv XR · DIN 02409100 · $0.7688
Jamp Guanfacine XR · DIN 02523558 · $0.7688
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02563185
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Guanfacine XR · DIN 02523736 · 2mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Guanfacine XR · DIN 02523736
Manufacturer: Apotex Inc.; listing date 2022-03-31
Health Canada: Marketed since 2022-01-31 · brand APO-GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG · company Apotex inc · schedule Prescription
Apo-Guanfacine XR: Formulary list price $0.9353/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9353 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101279 · Verify on the e-Formulary ↗ (DIN 02523736)
Source record
DIN 02523736: Apo-Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816002; group id 360; item number 0841; lccId 00326; manufacturer id APX
Source form: ER Tab; strength: 2mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.9353; ministry $0.9353
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523736
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101279
Interchangeable products
Intuniv XR · DIN 02409119 · $0.9353
Jamp Guanfacine XR · DIN 02523566 · $0.9353
Sandoz Guanfacine XR · DIN 02563193 · $0.9353
Shortage status: shortage reported ended 2026-07-16 (report last updated 2026-07-16); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523736
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Intuniv XR · DIN 02409119 · 2mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Savings card: innoviCares lists Intuniv XR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Intuniv XR · DIN 02409119
Manufacturer: Takeda Canada Inc.; listing date 2020-01-31
Health Canada: Marketed since 2021-07-29 · brand INTUNIV XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG · company Takeda canada inc · schedule Prescription
Ministry pays: $0.9353 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89384 · Verify on the e-Formulary ↗ (DIN 02409119)
Source record
DIN 02409119: Intuniv XR
Raw flags: sec12=Y, sec3=Y
Item: 240816002; group id 360; item number 0841; lccId 00326; manufacturer id TAK
Source form: ER Tab; strength: 2mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.7413; ministry $0.9353
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02409119
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89384
Interchangeable products
Apo-Guanfacine XR · DIN 02523736 · $0.9353
Jamp Guanfacine XR · DIN 02523566 · $0.9353
Sandoz Guanfacine XR · DIN 02563193 · $0.9353
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02409119
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Guanfacine XR · DIN 02523566 · 2mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Guanfacine XR · DIN 02523566
Manufacturer: Jamp Pharma Corporation; listing date 2022-03-31
Health Canada: Marketed since 2022-01-26 · brand JAMP GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG · company Jamp pharma corporation · schedule Prescription
Jamp Guanfacine XR: Formulary list price $0.9353/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9353 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101264 · Verify on the e-Formulary ↗ (DIN 02523566)
Source record
DIN 02523566: Jamp Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816002; group id 360; item number 0841; lccId 00326; manufacturer id JPC
Source form: ER Tab; strength: 2mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.9353; ministry $0.9353
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523566
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101264
Interchangeable products
Apo-Guanfacine XR · DIN 02523736 · $0.9353
Intuniv XR · DIN 02409119 · $0.9353
Sandoz Guanfacine XR · DIN 02563193 · $0.9353
Shortage status: resolved shortage (ended 2025-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523566
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Guanfacine XR · DIN 02563193 · 2mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Guanfacine XR · DIN 02563193
Manufacturer: Sandoz Canada Inc.; listing date 2026-05-29
Health Canada: Marketed since 2026-04-30 · brand SANDOZ GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Guanfacine XR: Formulary list price $0.9353/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9353 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106600 · Verify on the e-Formulary ↗ (DIN 02563193)
Source record
DIN 02563193: Sandoz Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816002; group id 360; item number 0841; lccId 00326; manufacturer id SDZ
Source form: ER Tab; strength: 2mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.9353; ministry $0.9353
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02563193
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106600
Interchangeable products
Apo-Guanfacine XR · DIN 02523736 · $0.9353
Intuniv XR · DIN 02409119 · $0.9353
Jamp Guanfacine XR · DIN 02523566 · $0.9353
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02563193
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Guanfacine XR · DIN 02523744 · 3mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Guanfacine XR · DIN 02523744
Manufacturer: Apotex Inc.; listing date 2022-03-31
Health Canada: Marketed since 2022-01-31 · brand APO-GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG · company Apotex inc · schedule Prescription
Apo-Guanfacine XR: Formulary list price $1.1019/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.1019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101280 · Verify on the e-Formulary ↗ (DIN 02523744)
Source record
DIN 02523744: Apo-Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816003; group id 360; item number 0842; lccId 00326; manufacturer id APX
Source form: ER Tab; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.1019; ministry $1.1019
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523744
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101280
Interchangeable products
Intuniv XR · DIN 02409127 · $1.1019
Jamp Guanfacine XR · DIN 02523574 · $1.1019
Sandoz Guanfacine XR · DIN 02563207 · $1.1019
Shortage status: shortage reported ended 2026-07-30 (report last updated 2026-07-30); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523744
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Intuniv XR · DIN 02409127 · 3mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Savings card: innoviCares lists Intuniv XR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Intuniv XR · DIN 02409127
Manufacturer: Takeda Canada Inc.; listing date 2020-01-31
Health Canada: Marketed since 2021-09-01 · brand INTUNIV XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG · company Takeda canada inc · schedule Prescription
Ministry pays: $1.1019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89385 · Verify on the e-Formulary ↗ (DIN 02409127)
Source record
DIN 02409127: Intuniv XR
Raw flags: sec12=Y, sec3=Y
Item: 240816003; group id 360; item number 0842; lccId 00326; manufacturer id TAK
Source form: ER Tab; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $4.4075; ministry $1.1019
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02409127
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89385
Interchangeable products
Apo-Guanfacine XR · DIN 02523744 · $1.1019
Jamp Guanfacine XR · DIN 02523574 · $1.1019
Sandoz Guanfacine XR · DIN 02563207 · $1.1019
Shortage status: resolved shortage (ended 2025-04-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02409127
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Guanfacine XR · DIN 02523574 · 3mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Guanfacine XR · DIN 02523574
Manufacturer: Jamp Pharma Corporation; listing date 2022-03-31
Health Canada: Marketed since 2022-01-27 · brand JAMP GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG · company Jamp pharma corporation · schedule Prescription
Jamp Guanfacine XR: Formulary list price $1.1019/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.1019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101265 · Verify on the e-Formulary ↗ (DIN 02523574)
Source record
DIN 02523574: Jamp Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816003; group id 360; item number 0842; lccId 00326; manufacturer id JPC
Source form: ER Tab; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.1019; ministry $1.1019
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523574
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101265
Interchangeable products
Apo-Guanfacine XR · DIN 02523744 · $1.1019
Intuniv XR · DIN 02409127 · $1.1019
Sandoz Guanfacine XR · DIN 02563207 · $1.1019
Shortage status: resolved shortage (ended 2025-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523574
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Guanfacine XR · DIN 02563207 · 3mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Guanfacine XR · DIN 02563207
Manufacturer: Sandoz Canada Inc.; listing date 2026-05-29
Health Canada: Marketed since 2026-04-30 · brand SANDOZ GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 3 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Guanfacine XR: Formulary list price $1.1019/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.1019 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106601 · Verify on the e-Formulary ↗ (DIN 02563207)
Source record
DIN 02563207: Sandoz Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816003; group id 360; item number 0842; lccId 00326; manufacturer id SDZ
Source form: ER Tab; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.1019; ministry $1.1019
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02563207
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106601
Interchangeable products
Apo-Guanfacine XR · DIN 02523744 · $1.1019
Intuniv XR · DIN 02409127 · $1.1019
Jamp Guanfacine XR · DIN 02523574 · $1.1019
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02563207
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Guanfacine XR · DIN 02523752 · 4mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Guanfacine XR · DIN 02523752
Manufacturer: Apotex Inc.; listing date 2022-03-31
Health Canada: Marketed since 2022-01-31 · brand APO-GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG · company Apotex inc · schedule Prescription
Apo-Guanfacine XR: Formulary list price $1.2685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101281 · Verify on the e-Formulary ↗ (DIN 02523752)
Source record
DIN 02523752: Apo-Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816004; group id 360; item number 0843; lccId 00326; manufacturer id APX
Source form: ER Tab; strength: 4mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2685; ministry $1.2685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523752
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101281
Interchangeable products
Intuniv XR · DIN 02409135 · $1.2685
Jamp Guanfacine XR · DIN 02523582 · $1.2685
Sandoz Guanfacine XR · DIN 02563215 · $1.2685
Shortage status: shortage reported ended 2026-08-06 (report last updated 2026-08-06); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523752
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Intuniv XR · DIN 02409135 · 4mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Savings card: innoviCares lists Intuniv XR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Intuniv XR · DIN 02409135
Manufacturer: Takeda Canada Inc.; listing date 2020-01-31
Health Canada: Marketed since 2021-07-26 · brand INTUNIV XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG · company Takeda canada inc · schedule Prescription
Ministry pays: $1.2685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89386 · Verify on the e-Formulary ↗ (DIN 02409135)
Source record
DIN 02409135: Intuniv XR
Raw flags: sec12=Y, sec3=Y
Item: 240816004; group id 360; item number 0843; lccId 00326; manufacturer id TAK
Source form: ER Tab; strength: 4mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $5.0738; ministry $1.2685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02409135
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89386
Interchangeable products
Apo-Guanfacine XR · DIN 02523752 · $1.2685
Jamp Guanfacine XR · DIN 02523582 · $1.2685
Sandoz Guanfacine XR · DIN 02563215 · $1.2685
Shortage status: resolved shortage (ended 2019-09-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02409135
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Guanfacine XR · DIN 02523582 · 4mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Guanfacine XR · DIN 02523582
Manufacturer: Jamp Pharma Corporation; listing date 2022-03-31
Health Canada: Marketed since 2022-01-27 · brand JAMP GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG · company Jamp pharma corporation · schedule Prescription
Jamp Guanfacine XR: Formulary list price $1.2685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101266 · Verify on the e-Formulary ↗ (DIN 02523582)
Source record
DIN 02523582: Jamp Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816004; group id 360; item number 0843; lccId 00326; manufacturer id JPC
Source form: ER Tab; strength: 4mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2685; ministry $1.2685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523582
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101266
Interchangeable products
Apo-Guanfacine XR · DIN 02523752 · $1.2685
Intuniv XR · DIN 02409135 · $1.2685
Sandoz Guanfacine XR · DIN 02563215 · $1.2685
Shortage status: resolved shortage (ended 2025-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523582
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Guanfacine XR · DIN 02563215 · 4mg · extended release tablet
Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
Write on scriptLU code 540 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540
For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Guanfacine XR · DIN 02563215
Manufacturer: Sandoz Canada Inc.; listing date 2026-05-29
Health Canada: Marketed since 2026-04-30 · brand SANDOZ GUANFACINE XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 4 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Guanfacine XR: Formulary list price $1.2685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106602 · Verify on the e-Formulary ↗ (DIN 02563215)
Source record
DIN 02563215: Sandoz Guanfacine XR
Raw flags: sec12=Y, sec3=Y
Item: 240816004; group id 360; item number 0843; lccId 00326; manufacturer id SDZ
Source form: ER Tab; strength: 4mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2685; ministry $1.2685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02563215
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106602
Interchangeable products
Apo-Guanfacine XR · DIN 02523752 · $1.2685
Intuniv XR · DIN 02409135 · $1.2685
Jamp Guanfacine XR · DIN 02523582 · $1.2685
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02563215
Shortage record checked 2026-09-13T08:10:21.292534+00:00